- 全部删除
您的购物车当前为空
TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.

TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 100 mg | 待询 | 待询 | |
| 500 mg | 待询 | 待询 |
TT-OAD2 free base 相关产品
| 产品描述 | TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. |
| 靶点活性 | GLP1 receptor:(EC50)5 nM |
| 体外活性 | TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells. |
| 体内活性 | TT-OAD2 ?treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice. |
| 分子量 | 856.83 |
| 分子式 | C50H47Cl2N3O6 |
| CAS No. | 1246826-07-2 |
| 密度 | 1.31g/cm3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容